Table 1.
Characteristics of included RCT studies
| Study (year) | Center | Location | Type of RVO | Primary endpoint | NO. of eyes | Age (year) | Sex (male/female) | Patient characteristics | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IVR 0.5 mg | IVR 0.3 mg | control | IVR 0.5 mg | IVR 0.3 mg | control | IVR 0.5 mg | IVR 0.3 mg | control | ||||||
| CRUISE (2010) | M | United States (95site) | CRVO | 6 m | 130 | 132 | 130 | 65.4 ± 13.1 | 69.7 ± 11.6 | 65.4 ± 13.1 | 80/50 | 71/61 | 72/58 | 1) Age > 18 y |
| 2) BCVA between 73 and 24 ETDRS letters | ||||||||||||||
| 3) RVO duration within 12 months | ||||||||||||||
| 4) CFT ≥ 250 μm | ||||||||||||||
| ROCC (2010) | M | Norway (4 sites) | CRVO | 6 m | 16 | 16 | NA | NA | NA | NA | 1) Age > 50 y | |||
| 2) BCVA between 73 and 6 ETDRS letters | ||||||||||||||
| 3) CFT ≥ 250 μm | ||||||||||||||
| BRAVO (2010) | M | United States (93site) | BRVO | 6 m | 131 | 134 | 132 | 65.2 ± 12.7 | 66.6 ± 11.2 | 65.2 ± 12.7 | 71/60 | 67/67 | 74/58 | 1) Age > 18 y |
| 2) BCVA between 73 to 24 ETDRS letters | ||||||||||||||
| 3) RVO duration within 12 months | ||||||||||||||
| 4) CFT ≥ 250 μm | ||||||||||||||
| Tan (2014) | M | Australia (5site) | BRVO | 12 m | 15 | 21 | 69.6 ± 11.6 | 66.7 ± 10.7 | 8/7 | 9/12 | 1) Age > 18 y | |||
| 2) BCVA between 68 to 20 | ||||||||||||||
| 3) RVO duration between 6 weeks to 9 months. | ||||||||||||||
| 4) CFT ≥ 250 μm | ||||||||||||||
RCT = prospective randomized controlled; RVO = retinal vein occlusion; IVR = intravitreal ranibizumab; M = multicenter; CRVO = central retinal vein occlusion; BCVA = best-corrected visual acuity; ETDRS = Early Treatment Diabetic Retinopathy Study; CFT = central foveal thickness; NA = not available; BRVO = branch retinal vein occlusion.